A plain language summary of the MIRACLE study: benralizumab in people in Asia with severe asthma
- PMID: 40931778
- PMCID: PMC12439564
- DOI: 10.1080/1750743X.2025.2550237
A plain language summary of the MIRACLE study: benralizumab in people in Asia with severe asthma
Plain language summary
What is this summary about?This summary describes the results of the Phase 3 MIRACLE study, originally published in the Respiratory Medicine journal. MIRACLE was the first clinical trial to evaluate the efficacy and safety of benralizumab injections in a large group of people from Asia with severe asthma.What were the main results of the MIRACLE study?People with severe asthma who took benralizumab had fewer asthma attacks (also called exacerbations). They also had better lung function, fewer asthma symptoms, better symptom control, and better health-related quality of life. The improvements in lung function and symptom control began as early as 4 weeks after the first benralizumab dose. A similar percentage of people in the benralizumab and placebo groups had adverse events.What do the results of MIRACLE mean?The MIRACLE results support the use of benralizumab as a treatment option for people in Asia with severe eosinophilic asthma. Benralizumab shows potential to improve asthma control and health-related quality of life in this population.[Box: see text].
Conflict of interest statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Nanshan Zhong, Kefang Lai, Dejun Sun, Ranran Dai, Ronnie Samoro and Hae-Sim Park report financial support from AstraZeneca. Annika Astrand, David Cohen, Maria Jison, Viktoria Werkstrom, Yuhui Yao, and Yajuan Zhang report a relationship with AstraZeneca that includes employment and equity or stocks. Vivian H Shih was an employee of AstraZeneca and may have held equity or stocks at the time of study design, analysis, and interpretation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Medical writing support was provided by Tanya Jandu and Helen Brereton of Springer Health+, Springer Healthcare Ltd, UK, and was funded by AstraZeneca.
Patient reviewers on this PLSP have received honorarium from
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
LinkOut - more resources
Full Text Sources